MIRM
Mirum Pharmaceuticals, Inc.
Latest Form 4:Sale$4.0MbyHowe Jolanda (SVP, GLOBAL CONTROLLER) · filed Aug 19, 2026
Mirum Pharmaceuticals, Inc. (MIRM) has 50 SEC Form 4 filings (106 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is Director Ramasastry Saira with 9 filings. Insiders have net sold $21.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Christopher Peetz
- Employees:334
- HQ:Foster City, CA, US
- IPO:2019-07-18
Insider Buying
$9.0M
reported purchases (SEC code P)
Insider Selling
$40.2M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$6.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| SVP, GLOBAL CONTROLLER | Sale | 40,000 | $4.0M | Aug 19 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 6,001 | $600K | Aug 12 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 20,000 | $2.0M | Aug 11 | SEC ↗ | |
| SVP, GLOBAL CONTROLLER | Sale | 1,840 | $194K | Aug 5 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 20,000 | $2.4M | Jul 8 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 5,000 | $611K | Jul 8 | SEC ↗ | |
| SVP, GLOBAL CONTROLLER | Sale | 2,721 | $327K | Jul 2 | SEC ↗ | |
Howe JolandaFirst in 3 months | SVP, GLOBAL CONTROLLER | Sale | 2,594 | $264K | Jun 18 | SEC ↗ |
| CHIEF FINANCIAL OFFICER | Sale | 5,000 | $469K | Jun 10 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 30,000 | $2.9M | Jun 2 | SEC ↗ | |
| Director | Sale | 3,977 | $398K | Jun 2 | SEC ↗ | |
| Director | Sale | 2,000 | $219K | May 19 | SEC ↗ | |
| Director | Sale | 2,000 | $194K | Apr 16 | SEC ↗ | |
| PRESIDENT AND COO | Sale | 16,515 | $1.5M | Mar 17 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 40,985 | $3.8M | Mar 17 | SEC ↗ | |
| SVP, GLOBAL CONTROLLER | Sale | 4,732 | $435K | Mar 17 | SEC ↗ | |
| Director | Sale | 2,000 | $182K | Mar 17 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 7,287 | $670K | Mar 17 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 7,287 | $670K | Mar 17 | SEC ↗ | |
| Director | Sale | 2,000 | $204K | Feb 17 | SEC ↗ | |
| SVP, GLOBAL CONTROLLER | Sale | 968 | $100K | Feb 3 | SEC ↗ | |
| PRESIDENT AND COO | Sale | 2,631 | $272K | Feb 3 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 9,108 | $941K | Feb 3 | SEC ↗ | |
| SVP, GLOBAL CONTROLLER | Sale | 842 | $81K | Jan 27 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,053 | $101K | Jan 27 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 6,831 | $657K | Jan 27 | SEC ↗ | |
| PRESIDENT AND COO | Sale | 3,143 | $302K | Jan 27 | SEC ↗ | |
Heron Patrick JFirst in 4 months | Director | Purchase | 131,425 | $9.0M | Jan 27 | SEC ↗ |
Radovich PeterFirst filing | PRESIDENT AND COO | Sale | 2,382 | $222K | Jan 23 | SEC ↗ |
Howe JolandaFirst filing | SVP, GLOBAL CONTROLLER | Sale | 926 | $86K | Jan 23 | SEC ↗ |
Peetz ChristopherFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 7,098 | $662K | Jan 23 | SEC ↗ |
| CHIEF MEDICAL OFFICER | Sale | 1,822 | $170K | Jan 23 | SEC ↗ | |
BJERKHOLT ERICFirst in 4 months | CHIEF FINANCIAL OFFICER | Sale | 1,421 | $133K | Jan 23 | SEC ↗ |
Quan JoanneFirst filing | CHIEF MEDICAL OFFICER | Sale | 6,911 | $624K | Jan 21 | SEC ↗ |
| Director | Sale | 2,000 | $182K | Jan 16 | SEC ↗ | |
| Director | Sale | 50,000 | $3.9M | Dec 23 | SEC ↗ | |
| Director | Sale | 5,000 | $400K | Dec 23 | SEC ↗ | |
Ramasastry SairaFirst in 3 months | Director | Sale | 2,000 | $139K | Dec 19 | SEC ↗ |
| Director | Sale | 50,000 | $3.7M | Dec 2 | SEC ↗ | |
GREY MICHAEL GFirst filing | Director | Sale | 50,000 | $3.5M | Nov 25 | SEC ↗ |
Brege LauraFirst filing | Director | Sale | 17,000 | $1.3M | Sep 12 | SEC ↗ |
BJERKHOLT ERICFirst filing | CHIEF FINANCIAL OFFICER | Sale | 9,578 | $728K | Sep 12 | SEC ↗ |
Ramasastry SairaFirst filing | Director | Sale | 17,000 | — | Sep 10 | SEC ↗ |
Related companies
Mirum Pharmaceuticals, Inc. is in the Healthcare sector.